Patent · US Active

Compounds for MALT1 degredation

US10689366B2 · kind B2 · utility

0Cited by
1References
19Claims
0Family size

Assignees

Inventors

Key dates

Filing dateOct 31, 2017
Grant dateJun 23, 2020
Priority date
Expiry dateOct 31, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are bifunctional compounds that inhibit MALT1 and/or promote targeted ubiquitination for the degradation of MALT1. In particular, provided are compounds that can bind MALT1, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALT1, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALT1, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.